Higher levels of antibodies to the tumour-associated antigen cyclin B1 in cancer-free individuals than in patients with breast cancer. (4th September 2014)

• Record Type: Journal Article
• Authors: Pandey, J P; Kistner-Griffin, E; Namboodiri, A M; Iwasaki, M; Kasuga, Y; Hamada, G S; Tsugane, S
• Is Part Of: Clinical and experimental immunology. Volume 178:Number 1(2014:Oct.)
• Page Start: 75
• Page End: 78
• Publication Date: 2014-09-04
• Subjects: antibodies -- breast cancer -- cyclin B1 -- immunosurveillance -- tumour-associated antigen; Immunopathology -- Periodicals; 616.079
• DOI: 10.1111/cei.12385
• Languages: English
• ISSNs: 0009-9104

Abstract

Summary: Cyclin B1 is a checkpoint protein that regulates cell division from G2 to the M phase. Studies in mice have shown that cyclin B1 vaccine-induced immunity significantly delayed or prevented the spontaneous cancer development later in life. We hypothesized that if these results showing a protective effect of anti-cyclin B1 antibodies could be extrapolated to the human condition, cancer-free individuals should have higher levels of endogenous antibodies than patients with cancers characterized by the over-expression of this tumour-associated antigen. To test this hypothesis, we characterized a large (1739 subjects) number of multi-ethnic patients with breast cancer (which over-expresses cyclin B1) and matched controls for anti-cyclin B1 immunoglobulin (Ig)G antibodies. Multivariate analyses, after adjusting for the covariates, showed that cancer-free individuals had significantly higher levels of naturally occurring IgG antibodies to cyclin B1 than patients with breast cancer (mean ± standard deviation: 148·0 ± 73·6 versus 126·1 ± 67·8 arbitrary units per ml; P < 0·0001). These findings may have important implications for cyclin B1-based immunotherapy against breast cancer and many other cyclin B1-over-expressing malignancies.